Nathan Bahary MD, PhD received his B.A. from Cornell University, an M.D. from the Cornell University School of Medicine, and his Ph.D. from the Rockefeller University. He completed his residency at Beth Israel Hospital in Boston. He did his postgraduate training at the Dana Farber Cancer Institute, Harvard, and Brigham and Women’s Hospital system before joining the faculty of UPMC as the Director of the Pancreatic Cancer Center. Since 2021, he is the Division Chief of Medical Oncology at AHN Cancer Institute and Director of AHNCI Clnical Research. Amongst his various appointments Dr. Bahary is a member of the NCI Pancreatic Task Force, the Eastern Cooperative Oncology Group (ECOG) where he serves on the ECOG GI Steering Committee and the American Society of Clinical Oncology (ASCO) His basic research interests lie in the intersection between gastrointestinal development, metabolic stress pathways, immunology, and cancer. He has a broad research background in cancer genetics, developmental biology, molecular biology, and clinical investigations, with specific training and expertise in key research areas broadly within the field of gastrointestinal oncology, and specifically within pancreatic cancer. Building on his work at Harvard Medical School, Dr. Bahary is using insights gained by studying vertebrate development to determine how cancers grow. Clinical trials emanating from this research will continue at AHN Cancer Institute and are expected to lead to the development of new targeted agents and immunologic strategies for treating cancer.